Latest 麻豆女优 Health News Stories
An Arm and a Leg: Wait, Is Insulin Cheaper Now?
Did the price of insulin go down? It鈥檚 not quite that simple. On this episode of 鈥淎n Arm and a Leg,鈥 producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
States Target Health Insurers鈥 鈥楶rior Authorization鈥 Red Tape
Doctors, patients, and hospitals have railed for years about the prior authorization processes that health insurers use to decide whether they鈥檒l pay for patients鈥 drugs or medical procedures. The Biden administration announced a crackdown in January, but some state lawmakers are looking to go further.
These Patients Had to Lobby for Correct Diabetes Diagnoses. Was Their Race a Reason?
Adults who develop one autoimmune form of diabetes are often misdiagnosed with Type 2 diabetes. Those wrong diagnoses make it harder to get the appropriate medications and technology to manage their blood sugar. Many Black patients wonder if their race plays a role.
Beyond Insulin: Medi-Cal Expands Patient Access to Diabetes Supplies
California鈥檚 Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
California Expands Paid Sick Days and Boosts Health Worker Wages
Gov. Gavin Newsom signed legislation expanding paid sick leave to five days, extending bereavement leave to miscarriages and failed adoptions, and approving an eventual $25-an-hour health care minimum wage. Still, in a possible sign of national ambitions, the Democrat vetoed free condoms in schools and refused to decriminalize psychedelic mushrooms.
New Weight Loss Drugs Carry High Price Tags and Lots of Questions for Seniors
Although nearly 40% of Americans 60 and older are obese, Medicare doesn鈥檛 cover weight loss medications. Meanwhile, studies haven鈥檛 thoroughly examined new drugs鈥 impact on older adults.
Many People Living in the ‘Diabetes Belt’ Are Plagued With Medical Debt
The 鈥淒iabetes Belt,鈥 as defined by the Centers for Disease Control and Prevention, comprises 644 mostly Southern counties where diabetes rates are high. Of those counties, 麻豆女优 Health News and NPR found, more than half also have high levels of medical debt.
Redes sociales alimentan obsesi贸n por las drogas para bajar de peso, sin hablar de riesgos
La competencia para hacerse con un mercado que podr铆a valer $100.000 millones al a帽o, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias聽 y m茅dicos de todo el mundo.
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren鈥檛 FDA-approved for that use.
What the Health? From 麻豆女优 Health News: The Confusing Fate of the Abortion Pill
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA鈥檚 approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join 麻豆女优 Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
Montana May Require Insurers to Cover Monitoring Devices for Diabetes
Montana is one of several states considering expanding coverage of continuous glucose monitors, but insurance companies and some providers argue that not all people with diabetes need them.
Journalists Delve Into Insulin Costs and Prior Authorization Policy
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Fresh Produce Is an Increasingly Popular Prescription for Chronically Ill Patients
Fresh produce prescription programs are getting a boost in Montana as a way of helping people with chronic conditions such as diabetes and high blood pressure. The approach may be a model for other rural states to promote healthy eating in food deserts.
California Picks Generic Drug Company Civica to Produce Low-Cost Insulin
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He鈥檚 also eyeing other generic drugs.
California eligi贸 a la compa帽铆a de gen茅ricos Civica para producir insulina de bajo costo
Civica est谩 desarrollando tres tipos de insulina gen茅rica, conocida como biosimilar, que estar谩n disponibles tanto en viales como en plumas inyectables, a un costo de entre $30 y $55.
La insulina representa lo perverso del sistema sanitario estadounidense, ya que los precios de venta de este medicamento centenario, del que dependen 8,4 millones de estadounidenses para sobrevivir, se quintuplicaron en dos d茅cadas.
Why Does Insulin Cost So Much? Big Pharma Isn鈥檛 the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it鈥檚 the arbitrators that jack up prices for those who can least afford them.
Journalists Discuss Insulin Prices, Gun Violence, Distracted Driving, and More
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Decisi贸n de Eli Lilly de bajar el precio de su insulina lograr谩 cambios hist贸ricos en los costos
Expertos en precios de medicamentos celebraron la noticia de Eli Lilly y otros esfuerzos. Y estas otras iniciativas para llevar al mercado insulina de menor costo, a su vez, presionar铆an a Eli Lilly para que mantuviera sus precios bajos.
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
